Rurelec PLC
22 September 2005
22 September 2005
Rurelec PLC ('Rurelec' or the 'Company')
Appointment of Director
The board of Rurelec announces the appointment of Sir Duncan Robin Carmichael
Christopher KBE CMG as of 14 September 2005 as a non-executive director of the
Company.
Sir Robin, aged 60, recently retired as the British Ambassador to Argentina, a
post he held for four years, and first lived in Latin America forty years ago.
He knows Bolivia well.
Sir Robin is a trustee for The Brooke Hospital, Prospect Burma and St. Matthew's
Children Fund (Ethiopia), all of which are charitable trusts. He is also an Hon.
Fellow of the Institute for the Study of the Americas (ISA) at London
University.
There is no further disclosure required pursuant to schedule 2(g) of the AIM
Rules.
Commenting on the appointment, Rurelec's Chairman, Jimmy West said 'I am
delighted to welcome Sir Robin to the Board and believe that his experience in
our target markets will assist the Company greatly in its further development'.
For further information, please contact:
Peter Earl, Managing Director Tel. 020 7793 7676
Paul Shackleton, Daniel Stewart & Co Tel. 020 7776 6578
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.